Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States
Few studies have addressed recent trends in hospitalization costs for inflammatory bowel disease (IBD).
We explored trends and described patient and hospital factors associated with hospitalization costs for IBD.
Using data from the 2003–2014 National Inpatient Sample for adults aged ≥ 18 years, we estimated costs using multivariable linear models and assessed linear trends by time periods using piecewise linear regressions.
In 2014, there were an estimated 56,290 hospitalizations for Crohn’s disease (CD), with a mean cost of US$11,345 and median cost of US$7592; and 33,585 hospitalizations for ulcerative colitis (UC), with a mean cost of US$13,412 and median cost of US$8873. Higher costs were observed among Hispanic [adjusted cost ratio (ACR) = 1.07; 95% confidence interval (CI) = 1.00–1.14; p = 0.04] or other non-Hispanic (ACR = 1.09; 95% CI = 1.02–1.17; p = 0.01) CD patients than for non-Hispanic White CD patients. For UC patients, higher costs were observed among men (ACR = 1.09; 95% CI = 1.05–1.13; p < 0.001) compared with women and among patients aged 35–44 years, 45–54 years, and 55–64 years compared with those aged 18–24 years. Among all patients, factors associated with higher costs included higher household income, more comorbidities, and hospitals that were government nonfederal versus private, were large versus small, and were located in the West versus Northeast regions. From 2003 to 2008, total costs increased annually by 3% for CD (1.03; 95% CI = 1.02–1.05; p < 0.001) and 4% for UC (1.04; 95% CI = 1.02–1.06; p < 0.001), but remained unchanged from 2008 to 2014.
The findings are important to identify IBD patients with higher hospitalization costs and to inform policy plans on hospital resource allocation.
Study design: FX, YL, JBC. Study analysis: FX, YL, KMR. Results interpretation: FX, YL, AGW, KMR, JBC. Manuscript writing: FX, YL, AGW, KMR, JBC. Manuscript approval: FX, YL, AGW, KMR, JBC.
Compliance with Ethical Standards
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
Conflict of Interest
Fang Xu, Yong Liu, Anne G. Wheaton, Kristina M. Rabarison, and Janet B. Croft have no conflict of interest in the study.
- 7.Crohn’s & Colitis Foundation. The facts about inflammatory bowel disease. 2014; http://www.crohnscolitisfoundation.org/assets/pdfs/updatedibdfactbook.pdf. Accessed 29 September 2017.
- 16.Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PD. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15(385–392):e382.Google Scholar
- 17.Agency for Healthcare Research & Quality. Data innovations—ICD-10-CM/PCS resources. 2017; https://www.hcup-us.ahrq.gov/datainnovations/icd10_resources.jsp. Accessed 3 January 2018.
- 18.Agency for Healthcare Research & Quality. Nationwide inpatient sample redesign report. 2018; https://www.hcup-us.ahrq.gov/db/nation/nis/reports/NISRedesignFinalReport040914.pdf. Accessed 3 January 2018.
- 19.IBM Watson Health. Putting research data into your hands with the MarketScan databases. 2018; http://truvenhealth.com/markets/state-and-medicaid/products/data-and-tools/marketscan-database. Accessed 12 January 2018.
- 20.Agency for Healthcare Research & Quality. Overview of the national (Nationwide) inpatient sample (NIS). 2017; https://www.hcup-us.ahrq.gov/nisoverview.jsp. Accessed 2 October 2017.
- 21.Truven Health Analytics. Commercial claims and encounters Medicare supplemental. 2017; https://marketscan.truvenhealth.com/marketscanuniversity/userguide/2015%20MarketScanCCAE-MDCRUserGuide.pdf.
- 22.Agency for Healthcare Research & Quality. Cost-to-charge ratio files. 2017; https://www.hcup-us.ahrq.gov/db/state/costtocharge.jsp#overview. Accessed 3 October 2017.
- 24.Statistics Bureau of Labor. Databases, tables and calculators by subject. 2017; https://data.bls.gov/timeseries/CUUR0000SA0.
- 25.Agency for Healthcare Research & Quality. Elixhauser comorbidity software, version 3.7. 2017; https://www.hcup-us.ahrq.gov/toolssoftware/comorbidity/comorbidity.jsp. Accessed 12 January 2018.
- 26.Agency for Healthcare Research & Quality. Overview of disease severity measures disseminated with Nationwide Inpatient Sample (NIS) and Kids’ Inpatient Database (KID). https://www.hcup-us.ahrq.gov/db/nation/nis/OverviewofSeveritySystems.pdf. Accessed 3 October 2007.
- 27.Agency for Healthcare Research & Quality. NIS description of data elements: HOSP_BEDSIZE—bedsize of hospital. 2008; https://www.hcup-us.ahrq.gov/db/vars/hosp_bedsize/nisnote.jsp. Accessed 3 January 2018.
- 41.Weiss AJ, Elixhauser A. Overview of hospital stays in the United States, 2012: Statistical Brief #180. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006.Google Scholar
- 43.Stranges E, Holmquist L, Andrews RM. Inpatient stays in rural hospitals, 2007: Statistical Brief #85. Healthcare Cost and Utilization Project (HCUP) statistical briefs. Rockville: Agency for Healthcare Research and Quality (US); 2006.Google Scholar